Abstract
A role for dopamine in the pathophysiology of depression was first proposed in 1975 and reviewed 20 years ago in this journal (1). The results of pharmacological treatment with dopaminergic drugs, however, have been inconclusive. Dopamine agonists such as pramipexole have shown modest clinical efficacy as antidepressants (2), and dopamine-releasing stimulants have either failed in randomized controlled trials or produced small and transient improvements in depressive symptoms (3). Furthermore, more efficacious antidepressants that modulate dopamine release or dopamine receptors also act on other monoamine receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
